Phase III Study of Weekly High-Dose Infusional Fluorouracil Plus Folinic Acid With or Without Irinotecan in Patients With Metastatic Colorectal Cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986

Henning Köhne, Claus; Van Cutsem, Eric; Wils, J.; Bokemeyer, Carsten; Elserafi, M.; P. Lutz, Manfred; Lorenz, M.; Reichardt, Peter; Rückle-Lanz, H.; Frickhofen, N.; J. Fuchs, Roland; Mergenthaler, H.‐G.; Langenbuch, T.; Vanhoefer, U.; Rougier, P; Voigtmann, R.; Müller, Lutz; Genicot, B.; Anak, Özlem; Nordlinger, Bernard

doi:10.1200/jco.2005.05.546

Public

Phase III Study of Weekly High-Dose Infusional Fluorouracil Plus Folinic Acid With or Without Irinotecan in Patients With Metastatic Colorectal Cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986

Published in Journal of Clinical Oncology • Jun 7, 2005

Authors:

Claus Henning Köhne

Eric Van Cutsem

J. Wils

Abstract

PURPOSE: To demonstrate that adding irinotecan to a standard weekly schedule of high-dose, infusional fluorouracil (FU) and leucovorin (folinic acid [FA]) can prolong progression-free survival (PFS). PATIENTS AND METHODS: Four hundred thirty patients with measurable or assessable metastatic colorect...

Subject

Medicine

Irinotecan

Folinic acid

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!